Ocular Therapeutix
Bedford
About Ocular Therapeutix
Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $1.2B
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: nasdaq:OCUL
- Website: ocutx.com
- Phone: (781)357-4000
Industries & Categories
Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/ocular-therapeutix-17444 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.